Joint Conduct

Malaysia central bank chastises MyCC for auto insurance case

Malaysia central bank chastises MyCC for auto insurance case

02 March 2017

The central bank of Malaysia yesterday lashed out at the country’s competition authority, claiming it overstepped its bounds and undermined consumers by charging nearly two dozen automotive insurance companies with breaking competition law.

Robot collusion and the future of online marketplaces

Robot collusion and the future of online marketplaces

02 March 2017

As the debate over internet regulation rages on, automated data processing systems in the online retail sector have received surprisingly little coverage. From Amazon to Skyscanner, price comparison softwares have become expected and even integral to modern living. But with the ease provided by the increasingly ubiquitous software has also come an easier pathway to collusion, and difficulties with regards to its prosecution.

CMA: pay-for-delay settlement “restrictive in its own right”

CMA: pay-for-delay settlement “restrictive in its own right”

01 March 2017

In its opening statement at the Competition Appeal Tribunal today, the UK competition authority said that pay-for-delay agreements between an antidepressant patent holder and generics manufacturers were “by nature antithetical to the competitive process”.

Generic drugmaker says it was pushed to be paid to delay

Generic drugmaker says it was pushed to be paid to delay

28 February 2017

Generics UK had “little choice” but to enter into a settlement with GlaxoSmithKline in an alleged pay-for-delay scheme, counsel to the generic drugmaker told the Competition Appeal Tribunal today.

Malaysian enforcer eyes €45 million fine on insurance companies

Malaysian enforcer eyes €45 million fine on insurance companies

28 February 2017

Malaysia’s Competition Commission last week said it plans to fine 22 insurance companies 213.45 million ringett (€45 million) for allegedly anti-competitive agreements with vehicle repair shops.

GSK lawyer: CMA paroxetine decision was “overreach”

GSK lawyer: CMA paroxetine decision was “overreach”

27 February 2017

The UK’s antitrust watchdog was wrong to paint patent settlements between GlaxoSmithKline and two generic drugmakers as an illegal pay-for-delay scheme, counsel to the pharmaceutical company told the Competition Appeal Tribunal today.

CAT panel questions GSK counsel on by-object restrictions

27 February 2017

A lawyer acting for GlaxoSmithKline today argued that the company’s patent settlements with two generic drugmakers cannot be painted as by-object restrictions of competition – but faced questions on his approach by members of the Competition Appeal Tribunal.

GSK and generic drugmakers prepare for marathon CMA court fight

GSK and generic drugmakers prepare for marathon CMA court fight

24 February 2017

Six companies are set to begin a marathon five-week appeal against the UK Competition and Markets Authority’s first pay-for-delay decision.

DG Comp investigation could reset dynamic between airlines and suppliers

DG Comp investigation could reset dynamic between airlines and suppliers

23 February 2017

If the European Commission decides to charge airline equipment manufacturers with violating competition law, it could help reset the dynamic between airlines and equipment suppliers, a lawyer acting on the case said yesterday.

Interchange fees must be lower, says Mauritian watchdog

Interchange fees must be lower, says Mauritian watchdog

20 February 2017

The Competition Commission of Mauritius’ investigative branch has recommended that credit and debit card interchange fees within the jurisdiction should be lowered to promote competition.